ZURICH (Reuters) – Novartis said on Monday its canakinumab drug to help treat non-small cell lung cancer failed a phase III trial.
The drug, used as an adjuvant treatment, did not meet its primary endpoint of disease-free survival, the Swiss company said.
(Reporting by John Revill; Editing by Christian Schmollinger)
